Difluprednate
FDA-approved product (emulsion, ophthalmic), marketed as Difluprednate, Durezol.
- Registered studies
- 25
- Lab records
- 0
- Pathogens at ≥40%
- 1 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Anterior uveitis
- Eye inflammation
- Inflammation
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Corticosteroids, potent (group iii); Corticosteroids, plain
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.
AI-predicted activity
AI prediction · nothing measured- MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae38.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis37.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
25registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredAutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Difluprednate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Trimetrexate GlucuronateExisting use: Other agents against amoebiasis and other protozoal diseases88.6% AI-predicted activityagainst E. coliLab records exist17 registered studies
- Folic AcidExisting use: Acne, Anemia, Anemia (phenotype) and 8 more87.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- MethotrexateExisting use: Acute lymphoblastic leukemia, Adenoma, Arthritis and 21 more86.8% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- PralatrexateExisting use: Cancer, Mature T-cell and NK-cell non-Hodgkin lymphoma, Neoplasm and 2 more82.2% AI-predicted activityagainst E. coli44 registered studies
- TriclosanExisting use: Phenol and derivatives, Medicated dressings with antiinfectives81.0% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Leucovorin CalciumExisting use: Osteosarcoma67.6% AI-predicted activityagainst E. coli50+ registered studies
- LevoleucovorinExisting use: Anemia, Colorectal adenocarcinoma, Colorectal cancer and 3 more67.6% AI-predicted activityagainst E. coli50+ registered studies
- PyrimethamineExisting use: Malaria, Toxoplasmosis64.6% AI-predicted activityagainst E. coliLab records exist50+ registered studies
- Copanlisib DihydrochlorideExisting use: Follicular lymphoma, Neoplasm, Neoplasm of mature B-cells63.5% AI-predicted activityagainst E. coli10 registered studies
- AfamelanotideExisting use: Erythropoietic protoporphyria62.6% AI-predicted activityagainst E. coli23 registered studies
- Rimegepant SulfateExisting use: Migraine disorder61.6% AI-predicted activityagainst E. coli50+ registered studies
- Histrelin AcetateExisting use: Neoplasm, Prostate adenocarcinoma, Prostate cancer61.6% AI-predicted activityagainst E. coli13 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)
NCT00616070 · start 2007-12
Registered record
- Registry ID
- NCT00616070
- Conditions
- Inflammation
- Interventions
- Difluprednate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2007-12
- Completion
- 2008-03
- Enrolment
- 120
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammationInterventionDifluprednate; PlaceboPhasePhase 3Registry statusCompletedStudy of Difluprednate Ophthalmic Emulsion in Postoperative Inflammation
NCT00406341 · start 2004-04
Registered record
- Registry ID
- NCT00406341
- Conditions
- Inflammation
- Interventions
- Difluprednate Ophthalmic Emulsion
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2004-04
- Completion
- 2005-03
- Enrolment
- 200
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammationInterventionDifluprednate Ophthalmic EmulsionPhasePhase 3Registry statusCompletedStudy of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation
NCT00406497 · start 2003-04
Registered record
- Registry ID
- NCT00406497
- Conditions
- Inflammation
- Interventions
- Difluprednate Ophthalmic Emulsion
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2003-04
- Completion
- 2003-07
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammationInterventionDifluprednate Ophthalmic EmulsionPhasePhase 2Registry statusCompletedStudy of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
NCT00406887 · start 2002-08
Registered record
- Registry ID
- NCT00406887
- Conditions
- Anterior Uveitis; Panuveitis
- Interventions
- Difluprednate Ophthalmic Emulsion
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-08
- Completion
- 2003-11
- Enrolment
- 140
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnterior Uveitis; PanuveitisInterventionDifluprednate Ophthalmic EmulsionPhasePhase 3Registry statusCompletedStudy of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis
NCT00407056 · start 2002-08
Registered record
- Registry ID
- NCT00407056
- Conditions
- Uveitis; Panuveitis
- Interventions
- Difluprednate Ophthalmic Emulsion
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2002-08
- Completion
- 2003-06
- Enrolment
- 20
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUveitis; PanuveitisInterventionDifluprednate Ophthalmic EmulsionPhasePhase 3Registry statusCompletedStudy of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
NCT00405496 · start 2000-03
Registered record
- Registry ID
- NCT00405496
- Conditions
- Anterior Uveitis
- Interventions
- Difluprednate Ophthalmic Emulsion
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2000-03
- Completion
- 2001-04
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAnterior UveitisInterventionDifluprednate Ophthalmic EmulsionPhasePhase 2Registry statusCompletedStudy of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation
NCT00407225 · start 1999-12
Registered record
- Registry ID
- NCT00407225
- Conditions
- Inflammation
- Interventions
- Difluprednate Ophthalmic Emulsion
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-12
- Completion
- 2000-10
- Enrolment
- 24
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammationInterventionDifluprednate Ophthalmic EmulsionPhasePhase 2Registry statusCompletedStudy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
NCT00429923
Registered record
- Registry ID
- NCT00429923
- Conditions
- Inflammation
- Interventions
- Difluprednate; Difluprednate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 219
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammationInterventionDifluprednate; Difluprednate; PlaceboPhasePhase 3Registry statusCompletedStudy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002b)
NCT00430092
Registered record
- Registry ID
- NCT00430092
- Conditions
- Inflammation
- Interventions
- Difluprednate; Difluprednate; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- 219
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionInflammationInterventionDifluprednate; Difluprednate; PlaceboPhasePhase 3Registry statusCompletedStudy of Difluprednate in the Treatment of Uveitis
NCT00501579
Registered record
- Registry ID
- NCT00501579
- Conditions
- Uveitis
- Interventions
- Difluprednate; Prednisolone Acetate
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionUveitisInterventionDifluprednate; Prednisolone AcetatePhasePhase 3Registry statusCompleted